Virtual Library
Start Your Search
J. Sun
Author of
-
+
P2.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 213)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Locoregional Disease – NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.03-038 - Whole Tumor Perfusion CT in Patients with NSCLC Treated with Endostar Combined with Concurrent Radiotherapy (ID 997)
09:30 - 09:30 | Author(s): J. Sun
- Abstract
Background:
Endostar was reported as an anti-angiogenic agent, which could inhibit new vessel formation in tumor. This study is to investigate the NSCLC response to Endostar combined with concurrent radiotherapy using volumetric perfusion CT.
Methods:
This study was performed with the approval of the local Medical Ethics Committee, and all the enrolled patients gave their written informed consent before the inclusion in the study. Six patients with NSCLC were involved in the current study. The histological subtype for each patient was confirmed by biopsy. All patients were treated with Endostar combined with concurrent radiotherapy for 7 weeks. Whole tumor perfusion CT was performed for all patients before treatment (baseline) and 4weeks after combined therapy on a dual-source CT. All images were reviewed in consensus by 2 radiologists. Blood flow (BF), blood volume (BV) and permeability (PMB) values for the whole tumor were calculated by an alternative deconvolution algorithm and then quantitatively assessed. These perfusion parameters before and after therapy were compared to investigate the therapy response of NSCLC.
Results:
Histology revealed adenocarcinoma (AC) in 3 patients and squamous cell carcinoma (SCC) in 3 patients. In SCC group, BF, BV and PMB at baseline were 116.2±34.57, 11.53±3.14 and 21.87±4.86. Four weeks after treatment, those perfusion values were 50.59±16.09, 4.58±1.26 and 10.70±1.05 respectively, which showed obvious decreasing trends compared with baseline data. In AC group, BF, BV and PMB at baseline were 66.58±5.82, 6.66±0.14 and 16.50±1.29, respectively. The parameters were 49.94±5.07, 5.45±1.34 and 13.2±1.67 respectively, which did not show obvious changes compared with baseline data. However, the tendency of perfusion parameters might vary considerably. Of 3 patients with AC, 1 case also showed decreasing trend of BF, BV and PMB after treatment compared with baseline data. On the basis of RECIST criteria, all the four cases (3 cases with SCC and 1 case with AC) that perfusion parameters showed obvious decreasing trend were classified as having a partial response (PR) to therapy, the remaining 2 cases with AC as having stable disease.
Conclusion:
The AC and SCC might respond differently to treatment with endostar combined with concurrent radiotherapy. The obvious decreasing trend of perfusion parameters after therapy might predict a better response to endostar combined with concurrent radiotherapy.
